115 related articles for article (PubMed ID: 32815796)
21. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
22. Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.
Deeks HM; Walters RK; Barnoud J; Glowacki DR; Mulholland AJ
J Chem Inf Model; 2020 Dec; 60(12):5803-5814. PubMed ID: 33174415
[TBL] [Abstract][Full Text] [Related]
23. In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.
Ghaleb A; Aouidate A; Ayouchia HBE; Aarjane M; Anane H; Stiriba SE
J Biomol Struct Dyn; 2022 Jan; 40(1):143-153. PubMed ID: 32799761
[TBL] [Abstract][Full Text] [Related]
24. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
[TBL] [Abstract][Full Text] [Related]
25. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
26. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
27. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs.
Bhardwaj VK; Singh R; Das P; Purohit R
Comput Biol Med; 2021 Jan; 128():104117. PubMed ID: 33217661
[TBL] [Abstract][Full Text] [Related]
29. Identification of Berbamine, Oxyacanthine and Rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: An in silico study.
Joshi T; Bhat S; Pundir H; Chandra S
J Mol Graph Model; 2021 Dec; 109():108028. PubMed ID: 34649146
[TBL] [Abstract][Full Text] [Related]
30. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
[TBL] [Abstract][Full Text] [Related]
31. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.
Mathpal S; Joshi T; Sharma P; Joshi T; Pundir H; Pande V; Chandra S
J Biomol Struct Dyn; 2022 Feb; 40(3):1084-1100. PubMed ID: 32940134
[TBL] [Abstract][Full Text] [Related]
32. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
[TBL] [Abstract][Full Text] [Related]
33.
Huynh T; Wang H; Luan B
J Phys Chem Lett; 2020 Jun; 11(11):4413-4420. PubMed ID: 32406687
[TBL] [Abstract][Full Text] [Related]
34. Potential inhibitors for the novel coronavirus (SARS-CoV-2).
Han Y; Wang Z; Ren J; Wei Z; Li J
Brief Bioinform; 2021 Mar; 22(2):1225-1231. PubMed ID: 32942296
[TBL] [Abstract][Full Text] [Related]
35. Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study.
Reyaz S; Tasneem A; Rai GP; Bairagya HR
J Mol Graph Model; 2021 Dec; 109():108021. PubMed ID: 34537554
[TBL] [Abstract][Full Text] [Related]
36. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
37. De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations.
Arshia AH; Shadravan S; Solhjoo A; Sakhteman A; Sami A
Comput Biol Med; 2021 Dec; 139():104967. PubMed ID: 34739968
[TBL] [Abstract][Full Text] [Related]
38. Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins.
Thirumalaisamy R; Aroulmoji V; Iqbal MN; Deepa M; Sivasankar C; Khan R; Selvankumar T
J Mol Struct; 2021 Aug; 1238():130457. PubMed ID: 33867575
[No Abstract] [Full Text] [Related]
39. Isolation and In Silico Prediction of Potential Drug-like Compounds with a New Dimeric Prenylated Quinolone Alkaloid from
Zohora FT; Azam ATMZ; Ahmed S; Rahman KM; Halim MA; Anwar MR; Sohrab MH; Tabassum F; Hasan CM; Ahsan M
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500282
[TBL] [Abstract][Full Text] [Related]
40.
Mani M; Vellusamy M; Rathinavel T; Vadivel P; Dauchez M; Khan R; Aroulmoji V
J Biomol Struct Dyn; 2024 Mar; ():1-15. PubMed ID: 38533826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
